Biogen appoints Priya Singhal as executive vice president and head of de velopment
Biogen Inc has announced that Priya Singhal MD MPH and current head of global safety and regulatory sciences and interim head of research and development, has been promoted to the role of executive vice president and head of development. Singhal’s promotion follows a decision to split R&D into two separate functions, both of which will report to the CEO directly.
Biogen is therefore also looking for a new executive vice president and head of research, although Singhal will also be covering this role until a new employee is appointed.
Singhal has previously worked as senior vice president and head of global safety and regulatory sciences and interim head of R&D at Biogen, as well as overseeing Japan and China R&D. Prior to this she worked as head of R&D and manufacturing at Zafgen Inc, vice president of clinical trials and benefit risk management at Biogen, vice president of medical affairs at Vertex Pharmaceuticals, and led the benefit-risk for Velcade and two compounds in the development portfolio at Millennium Pharmaceuticals, where she began her drug-development career.
Christopher A. Viehbacher, president and chief executive officer at Biogen, commented: “Throughout her tenure at Biogen, Priya has demonstrated excellent leadership and judgement. In this new role, Priya will focus on delivering on our development programmes while working closely with a new dedicated head of research to strengthen Biogen’s translational science capabilities. We believe having two dedicated leaders will enhance productivity in bringing to patients worldwide medicines to treat some of the most challenging diseases, while assuring better risk management and resource stewardship.”
Pharmaceutical Industry news, analysis and insights